ASTH — Astrana Health, Inc.

Summary of Astrana Health, Inc. Q4 2025 Earnings Call

1. Key Financial Results and Metrics:

• Q4 2025 Results:
  • Total Revenue: $950.5 million (up 43% YoY)
  • Adjusted EBITDA: $52.5 million (up 50% YoY)
  • Net Income: $6 million; EPS: $0.12 (compared to a loss of $0.15 in Q4 2024)
  • Adjusted EPS: $0.54
• Full Year 2025 Results:
  • Total Revenue: $3.2 billion (up 56% YoY)
  • Adjusted EBITDA: $205.4 million (up 21% YoY)
  • Free Cash Flow: $104.5 million
  • Non-GAAP Adjusted EPS: $2.20

2. Strategic Updates and Business Highlights:

• Astrana Health is focused on building a patient-centered, payer-agnostic healthcare platform, emphasizing high-quality, accessible care.
• Membership in value-based care arrangements reached 1.6 million, with significant growth in both core (California) and expansion markets (90% YoY growth outside California).
• The company has successfully integrated the Prospect Health acquisition, achieving strong provider engagement with over 97% retention among primary care physicians.
• The proprietary technology platform continues to enhance operational efficiency, with G&A as a percentage of revenue decreasing to 6.8%.

3. Forward Guidance and Outlook:

• 2026 Guidance:
  • Revenue: $3.8 billion to $4.1 billion
  • Adjusted EBITDA: $250 million to $280 million
  • Free Cash Flow: $105 million to $132.5 million
• Q1 2026 Expectations:
  • Revenue: $900 million to $1.0 billion
  • Adjusted EBITDA: $60 million to $70 million
• The guidance reflects a conservative approach, accounting for potential Medicaid and exchange disenrollments and other headwinds.

4. Bad News, Challenges, or Points of Concern:

• The company is facing challenges related to elevated medical cost trends across the industry, with expected increases in Medicaid disenrollments (10%+) and adverse selection impacts.
• A material weakness in internal controls over financial reporting was identified, leading to a Form 12b-25 filing, although no material misstatements were reported.
• The guidance incorporates conservative assumptions regarding medical cost trends, which could impact profitability.

5. Notable Q&A Insights:

• Cost trends for 2026 are projected to be slightly over 5%, with Medicare Advantage expected to be lower than this average.
• The wider EBITDA guidance range for 2026 reflects various headwinds and tailwinds, including anticipated synergies from the Prospect acquisition and potential declines in Medicaid enrollment.
• The company remains confident in its ability to meet its 2027 EBITDA target of $350 million, even amidst potential rate pressures from Medicare Advantage.
• AI tools are being leveraged to improve operational efficiency and reduce costs, with ongoing investments in technology expected to yield further G&A improvements.

Overall, Astrana Health, Inc. reported strong financial performance in 2025, driven by strategic growth and operational efficiency, while navigating challenges in the healthcare landscape. The company maintains a cautious yet optimistic outlook for 2026, emphasizing disciplined growth and risk management.